ImmunoGen Inc (IMGN)

[skitahoe]

Today's new lows based on CFO leaving after charges at another company being validated is a buying opportunity IMHO, I purchased near these lows last week, but for any who haven't, it ought to be a consideration.

By this time next week we should have ASH results for our two newest drugs in trials. I also believe by year's end we'll learn that the Phase 3 for IMGN853 is unblinded, and the data's being collected. Hopefully we'll have top line data early next year. If all of this is positive, I cannot help but believe that we'll be seeing new 52 week highs, rather than lows, in the very near time future. Results of partners trials during the next few months could also add to positive sentiment toward the company.

Depending on the timing of the data gathering and submission of a BLA, approval of IMGN853 should occur either late 2019 or early 2020. Of course this assumes the data continues to be positive in the trial.

Gary